Mounjaro and your GP: what they can and can't do

The myth: your GP should be able to prescribe Mounjaro for weight loss now

This is the assumption that brings a lot of frustration. People see Mounjaro discussed everywhere, NICE recommended it in December 2024, and the reasonable conclusion is that any GP can now write a prescription for it. The reality is more constrained than that.

NHS GP prescribing of tirzepatide for weight management only became possible from 1 April 2026, when it was folded into the new GP contract under QOF 2026/27. Crucially, participation in that contract item is optional, practices can choose whether or not to take it on. Even practices that do participate are currently only commissioned to prescribe for patients who meet the current NHS cohort criteria: a BMI of 40 or above, combined with four or more of a defined list of five weight-related conditions (high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes).

A second cohort (BMI 35 to 39.9 with four or more of those same conditions) was activated in June 2026. But that still leaves out the majority of adults who are clinically overweight or obese. NHS criteria are designed to concentrate scarce resource on the highest-need patients first. That is sensible public health policy; it just means most people asking their GP about Mounjaro UK-wide will be told no, at least for now. Understanding why a GP cannot prescribe it in your case is worth doing before exploring alternatives.

What your GP's role actually is, even when they can't prescribe

Even if your practice isn't currently prescribing Mounjaro, your GP is not irrelevant. Several things are worth discussing with them regardless of which route you pursue.

Certain medical histories (including a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or a history of pancreatitis) affect whether tirzepatide is clinically appropriate. A GP who knows your full record is well placed to flag these. They also hold your Summary Care Record, which a prescribing pharmacist may cross-reference when assessing your consultation. NHS England guidance recommends that healthcare teams be informed when a patient starts a GLP-1 medicine, both for safety and for joined-up care.

If you do start treatment through a private route and later develop a side effect that needs urgent attention (the kind of severe stomach pain that can signal pancreatitis, for instance) your GP is the right first call, alongside emergency services if needed. The Mounjaro overview covers what to watch for in more detail. Keeping your GP in the loop is a matter of safety, not box-ticking.

There is also the question of monitoring. NICE's appraisal of tirzepatide (TA1026) notes that treatment should be reviewed at six months: if weight loss falls below 5% on the highest tolerated dose, continuing may not be justified. A GP who knows you're on treatment can factor that into their clinical picture.

Private prescribing: a separate legal route that doesn't need GP sign-off

For people who don't meet NHS criteria, or who simply don't want to wait, a private prescription from a regulated pharmacy is entirely lawful. It does not require your GP to refer you or approve the decision. What it does require is a proper clinical assessment by a registered prescriber, the same standard of care the rules demand from any source.

The distinction between NHS and private routes for Mounjaro comes down to eligibility thresholds and funding, not legality. Private eligibility broadly follows the licensed indication: adults with a BMI of 30 or above, or 27 or above with a weight-related condition, subject to the prescriber's overall assessment. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

The cost context is worth knowing plainly. Since Eli Lilly raised UK list prices in September 2025, private Mounjaro has typically ranged from around £149 to £375 per month depending on dose and provider, as widely reported. If you want to understand what drives that variation, the Mounjaro cost guide breaks it down. One thing worth knowing: at a clinically regulated pharmacy, a transparent price should include the prescription and clinical oversight, not just the pen.

At nume, every consultation is reviewed personally by a GPhC-registered Independent Prescriber (a real clinician reads your answers the same day) not software routing a form. You can verify our pharmacy registration on the GPhC register (premises number 9012878). If you're considering a private route, that kind of verification is the right place to start for any pharmacy you're looking at.

If you've been refused by a GP: what that actually means

A GP declining to prescribe Mounjaro almost certainly means one of two things: your practice isn't participating in the commissioning arrangement, or you don't meet the current NHS cohort criteria. Neither is a clinical verdict that you're unsuitable for the medicine. It's a funding and commissioning boundary, which is a different thing entirely.

It can feel dismissive. Many people find that after years of trying to manage weight through diet and exercise, being told the medicine they've read about isn't available through their GP is genuinely discouraging. That frustration is reasonable.

Knowing whether you can get Mounjaro via a GP under NHS criteria (and what your options are if not) is worth working out clearly before you do anything else. The weight loss treatment overview covers both NHS and private routes side by side. A private consultation is one path, and it starts with a clinical assessment that looks at your whole picture, not just your BMI against a commissioning threshold. If that's the route that suits you, starting a free consultation is the first step.